Thomas P. Rice Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
WOODCLIFF LAKE, N.J., June 12 /PRNewswire-FirstCall/ -- Par
Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced that Thomas P. Rice has been elected to the company's board of directors. Mr. Rice was also appointed to the Audit Committee and the Nominating-Corporate Governance Committee....
Stay on Par this Golf Season, Injury Free
Orthopaedic surgeons offer tips to minimize golf-related injuries
ROSEMONT, Ill., May 19 /PRNewswire-USNewswire/ -- Swinging the club on the open green, hitting the perfect shot and playing in the warm sun are just a few things golfers love about hitting the links. Golfing can be a treat ...
Federal Trade Commission Files Complaint Against Par Pharmaceutical Over Court-Approved AndroGel(R) Litigation Settlement
WOODCLIFF LAKE, N.J., Feb. 2 /PRNewswire-FirstCall/ -- Par
Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced that it learned after the close of business on Friday, January 30, 2009 that the Federal Trade Commission and the California Attorney General filed a lawsuit against Par
in the ...
MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
MonoSol Rx to initiate pivotal trials for ondansetron thin film immediately
WARREN, N.J. and PORTAGE, Ind., June 17 /PRNewswire/ -- MonoSol Rx, a
drug delivery company specializing in dissolving thin film pharmaceutical
products, and Strativa Pharmaceuticals, the proprietary products division
Nurturing Our Nurses for Healthcare Par Excellence
'Nurses - one of the few blessings of being ill' - Sara Moss-Wolfe
Nobility, thy name is Nursing Care, comfort, and compassion are traits sacrosanct to the nursing profession , just as dedication and patience are its greatest virtues. It might seem implausible to visualize these att...
Dogs Reasoning on Par With Human Toddlers: Study
They are mans best friends, and now dogs have surprised researchers by showing that they are capable of advanced reasoning as much as human toddlers.
The study, by Austrian researchers, shows that dogs behaviour is pretty sophisticated when it comes to a physical problem-solving test.
Blacks Get Treatment on Par With Whites for Cardiovascular Disease
Health outcomes for blacks with cardiovascular disease are similar or better than those of whites when differences in access and treatment are minimized, according to a study// published in the American Heart Journal, Reuters reports.
For the study, Nancy Kressin of the Edith Nourse Rogers M...
India On Par with South Africa in AIDS Count
Recent survey conducted by UNAIDS has put India on par
with South Africa. It has been revealed that these two countries have the highest estimated number of HIV infected people//.
The number of people living with HIV according to the UNAIDS 2006 Report on the Global AIDS Epidemic is 5.7 million...
Elders Too Are Keen To Chat On Internet On Par With Youngsters
According to a recent online survey, aging in no way deter the elders from chatting or surfing the Internet and said that they too are keen in using the net on par// with the youngsters.
The survey conducted by the Internet and Mobile Association of India with Crosstab Marketing Services has r...
Labopharm Reports Results for Second Quarter Fiscal 2009
Shareholders' equity (deficiency)
Common shares, no par
authorized shares, 57,000,533 and
56,826,063 issued as at June 30, 2009
and December 31, 2008, respectively ...
PAR in Medical Technology
Spherix Reports First Quarter 2009 Earnings
Preferred stock, $0.01 par
2,000,000 shares authorized;
... - -
Common stock, $0.005 par
50,000,000 shares authorized;
Paid-in capital in excess of par
value 27,610,426 27,602,486
Bionovo Announces First Quarter 2009 Highlights and Financial Results
Preferred stock, $0.0001 par
10,000,000 shares authorized; none
issued and outs...ding - -
Common stock $0.0001 par
190,000,000 shares authorized,
76,363,101 and 76,3...
Strativa Pharmaceuticals Provides Product Pipeline Update
... products division of a wholly owned subsidiary of par
Pharmaceutical Companies, Inc. (NYSE: PRX ), tod...aceuticals is the proprietary products division of par
Pharmaceutical, Inc. Strativa is committed to deve...ease visit www.strativapharma.com .
Elbow Ligament Reconstruction Appears Not to Affect Future Professional Advancement in Baseball
...it is heartening to see that the procedure can be successful in allowing future professional athletes to the reach the highest level of competition on par
with their peers," said Carolan.
The American Orthopaedic Society for Sports Medicine (AOSSM) is a world leader in sports medicine education, res...
Pharmasset Reports Fiscal Year End 2008 Financial Results
...bilities 33,794,724 16,908,073
COMMITMENTS & CONTINGENCIES
Common Stock, $0.001 par
100,000,000 shares authorized,
23,340,498 and 21,232,991
shares issued and outstanding
at September 30,...
Alfacell Provides ONCONASE(R) NDA Submission Update
...iple molecular mechanisms of action.
Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of par
Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with Megapharm Ltd. for Israel, BL&H Co. Ltd....
SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
...ckholders' Equity Preferred stock, authorized 5,000,000 shares, $.01 par
value, none issued or outstanding - - Common stock, authorized 100,000,000 shares, $.001 par
value, 41,130,270 and 40,991,385 issued and outstanding as of Septe...
FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
...FS is an effective prophylactic
FVIII replacement product has 'jump started' the standard of hemophilia
care in the United States so that it is now on par
with other developed
countries, especially those in Western and Northern Europe."
The FDA approval of Kogenate(R) FS for routine prophylaxis in chil...
Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
...45 16,908,073 -------------------------- COMMITMENTS
STOCKHOLDERS' EQUITY Common Stock, $0.001 par
value, 100,000,000 shares authorized, 21,751,503 and 21,232,991 shares issued and outstanding at June 30, 2008 (unaudited) and September 30, 200...
MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development
...uding the recently announced licensing of
our thin film formulation of ondansetron, an anti-emetic therapy, to
Strativa Pharmaceuticals, a division of par
expectation is to partner our PharmFilm(R) escitalopram oxalate product
with a pharmaceutical company that is competitively posit...
PAR in Biological News
Hypertension among lower-status employees lingers well into retirement
... be an additional 2.1 million people in the United States with job-related hypertension.
Leigh hopes that this study will help bring job history on par
with lifestyle factors when physicians consider hypertension risks with their patients.
"Even among the obese, we found that occupation correlated ...
Exhibition showcases the 'art of science'
...spired by science.
"This show exuberantly supports the idea that images produced in the pursuit of science can have an aesthetic value that is on a par
with art created for art's sake," said Andrew Zwicker, the head of Science Education at the Princeton Plasma Physics Laboratory (PPPL) and a lecturer ...
Difference in fat storage may explain lower rate of liver disease in African-Americans
...o be based on gender. Caucasian males are at the highest risk for NAFLD, on par
with the risk faced by Hispanics in general. Caucasian females are on par
with the African-American population, at about 23 percent. Caucasian female...
Cellulosic biofuel technology will generate low-cost green fuel, says major study
The researchers also found that the mature cellulosic biofuel technologies analysed:
Have the potential to realise efficiencies on par
with petroleum-based fuels.
Require modest volumes of process water.
Achieve production costs consistent with gasoline when oil prices are at about ...
Beckman Coulter Updates 2008 Outlook
...mpany estimates that, based on current exchange rates, full year
2008 revenue should increase by about 12%. Operating margins are anticipated
to be on par
with prior year results, between 11.5% and 12%. Non operating
expense should be about $48 million. Therefore, earnings per share
UAF researchers to present at AGU press briefing
...emical and geophysical measurement techniques, a first in the area. He also noted that while the high-arctic ocean readings were surprisingly high, on par
with those from high-arctic lakes, they are still much lower than is being found in subarctic regions.
"That means we cannot extrapolate the subarc...
Study rules out inbreeding as cause of amphibian deformities
...missing, extra or dwarfed digits (equivalent to fingers and toes). That is double the rate of malformation found in newts, a related amphibian, but on par
and with frequencies seen in many frog species, said assistant professor of forestry and natural resources Rod Williams.
"This is really the first ...
Synaptics Reports Record Results for First Quarter of Fiscal 2009
Stockholders' equity: Preferred stock; $.001 par
value; 10,000,000 shares authorized; no shares issued and ... - - Common stock; $.001 par
value; 60,000,000 shares authorized; 42,835,461 and 42,500,...
Geologist who linked cosmic strike to dinosaurs' extinction takes top prize
...er, World War II military leader and pioneer in transatlantic air travel. Vetlesen passed away in 1955. Designed to recognize sweeping achievements on par
with the Nobel (which has no regular prize in earth sciences) it is given every several years by a jury appointed by the president of Columbia Univers...
Oceans on the precipice: Scripps scientist warns of mass extinctions and 'rise of slime'
...ngs of the National Academy of Sciences ( PNAS ), Jackson believes that human impacts are laying the groundwork for mass extinctions in the oceans on par
with vast ecological upheavals of the past.
He cites the synergistic effects of habitat destruction, overfishing, ocean warming, increased acidific...
PAR in Biological Technology
Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
WOODCLIFF LAKE, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Strativa
Pharmaceuticals, the proprietary products division of a wholly owned
subsidiary of Par
Pharmaceutical Companies, Inc. (NYSE: PRX ) today
announced that its development partner, Immtech Pharmaceuticals, Inc.
(Amex: IMM ) has cho...
Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Pafuramidine on Clinical Hold Loramyc(R) Completes Patient Enrollment Ahead of Schedule Zensana(TM) Reformulation Complete, Resubmission on Target
WOODCLIFF LAKE, N.J., Dec. 28 /PRNewswire-FirstCall/ -- Par
Pharmaceutical Companies, Inc. (NYSE: PRX ) today pro...
Novavax Reports Second Quarter 2009 Financial Results
...compared to $33.9 million as of December 31, 2008. The company's short-term investments consist of investments in five auction rate securities with a par
value of $8.1 million and a fair value of $6.0 million. In addition to the other than temporary impairment discussed above, during the second quarter ...
American Oriental Bioengineering Reports Second Quarter 2009 Financial Results
Preferred stock, $0.001 par
2,000,000 shares authorized;
1,000,000 shares issued and
...pectively 1,000 1,000
Common stock, $0.001 par
150,000,000 shares authorized;
78,301,439 and 78,249,264 s...
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... 275.0 291.3
Total liabilities 2,652.2 2,635.2
Common stock of 5p par
value; 1,000 million
shares authorized; and 560.3 million shares
issued and outstanding (2008: 1,000 million
shares authorized; and 560.2 ...
NxStage Reports Second Quarter 2009 Financial Results
Undesignated preferred stock: par
$0.001, 5,000,000 shares authorized; no
shares issu...December 31, 2008 - -
Common stock: par
value $0.001, 100,000,000
shares authorized; 46,658,515 and
ERT Reports Second Quarter 2009 Results
Preferred stock-$10.00 par
shares authorized, none issued and
outstanding... - -
Common stock-$.01 par
shares authorized, 59,950,257 and
Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.
Common stock 201.8 201.8
Capital in excess of par
value 137.8 133.0
Common stock in treasury (1,953.5) (1,935.3)
Retained earnings ...
Essilor : First Half 2009 Revenue
...targeted acquisitions dynamic.
In light of these factors, Essilor is confident in its ability to
maintain first-half 2009 operating margin on a par
with full-year 2008.
Consolidated revenue for the first six months of 2009
EUR millions H1 2009 H1 2008 % Change % Change Con...
Vasogen Announces Second Quarter 2009 Results
... 1,288 1,242
Unlimited common shares, without par
Issued and outstanding:
22,623,195 common shares
(November 30, 2008 - 22,424,719) 365,730 365,677